網誌文章搜尋建議

給多發性硬化症MS病友和親友的建議:
如要搜尋站內相關文章可多利用
"搜尋此網誌的文章內容"的功能,這樣就可以快速的找到你想要得資訊而不需要從第一篇開始看了.
有關CCSVI(靜脈血管窄化及手術的資訊)可在相關連結以及相關MS blog內

推薦頻道:Gimmy a break

2010年10月12日 星期二

ECTRIMS 2010: Gothenburg, 瑞典 · 13-16 October 2010

26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 15th Conference of Rehabilitation in Multiple Sclerosis (RIMS) which will be held in Gothenburg, Sweden, 13–16 October 2010.
第26屆歐洲MS治療研究委員會議以及第15屆MS復健研討會將於十月13-16在瑞典Gothenburg展開

In past years, Dr. Zamboni was allowed to present a poster for display on his research of CCSVI in MS and iron deposition in MS brains, as it related to chronic venous disease. He has never been invited to speak before. Dr. Zamboni will be presenting his research along with Dr. Zivadinov in the Main Auditorium as part of the Charcot Foundation presentation, as they go up against Dr. Omar Khan, co-author of the first negative opinion piece in the Annals of Neurology: To say that this is a big deal is an understatement.

予會邀請的醫師來自英國,德國, 波蘭, 義大利, 甚至美國, 各方的研究和觀察到的最新資訊,不同的結果.
附上會議討論的議程特別針對CCSVI的研究現況如下:

Wednesday, October 13, 2010 12:35 - 12:45 European Charcot Foundation Chronic cerebrospinal venous Insufficiency. Relation to multiple sclerosis? (Main Auditorium)

CCSVI: from hypothesis to reality P. Zamboni (Ferrara, IT) (義大利醫師桑伯尼的研究)

12:45 - 13:00 European Charcot Foundation Chronic cerebrospinal venous Insufficiency. Relation to multiple sclerosis? (Main Auditorium) CCSVI: relation to multiple sclerosis R. Zivadinov (Buffalo, US)

13:15 - 13:30 European Charcot Foundation Chronic cerebrospinal venous Insufficiency. Relation to multiple sclerosis? (Main Auditorium) Questions on CCSVI in multiple sclerosis O. Kahn (Detroit, US)

On Thursday, Dr. Zivadinov is presenting results from the BNAC MRI studies -(美國水牛城醫學中心的研究)

Thursday, October 14, 2010 15:30 - 17:00 Imaging 1 MRI results of blinded chronic cerebrospinal venous insufficiency study in patients with multiple sclerosis, healthy controls and patients with other neurologic diseases P 318

R. Zivadinov, G. Cutter, K. Marr, M. Ramanathan, R.H.B. Benedict, M. Elfadil, N. Bergsland, C. Morgan, E. Carl, D. Hojnacki, E. Yeh, L. Willis, M. Cherneva, S. Hussein, J. Durfee, C. Kennedy, M. Dwyer, B. Weinstock-Guttman (Buffalo, Birmingham, US)

Also being presented is the genetics research now completed at BNAC (美國水牛城醫學中心的研究)

15:30 - 17:00 Genetics/transcriptomics 1 Associations of HLA DR*1501 status and chronic cerebrospinal venous insufficiency in multiple sclerosis P 265

B. Weinstock-Guttman, R. Zivadinov, G. Cutter, M. Tamano-Blanco, D. Badgett , K. Marr, E. Carl, M. Elfadil, C. Kennedy, M. Ramanathan (Buffalo, Birmingham, US)

Dr. Zamboni presents results from his endovascular treatment study-(義大利醫師桑伯尼的研究)

15:30 - 17:00 Therapy disease-modifying - Others 1 Endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis. A longitudinal pilot study P 508

P. Zamboni, R. Galeotti, B. Weinstock-Guttman, G. Cutter, E. Menegatti, A.M. Malagoni, D. Hojnacki, M. Dwyer, N. Bergsland, M. Hiennen-Brown, A. Salter, C. Kennedy, I. Bartolomei, F. Salvi, R. Zamboni (Ferrara, IT; Buffalo, Birmingham, US; Bologna, IT)

On Friday, a negative study is being presented by another Italian team who found no CCSVI in CIS patients.

Friday, October 15, 2010 09:45 - 10:00 Platform presentation of selected abstracts I (Congress Hall) No evidence of chronic cerebrospinal venous insufficiency in clinically isolated syndrome suggestive of multiple sclerosis 81

C. Baracchini, P. Perini, M. Calabrese, F. Causin, F. Farina, F. Rinaldi, P. Gallo (Padua, IT)

Then Dr. Zivadinov will present on how the visibility of lower brain vasculature ties into CCSVI severity as shown by MRI

10:00 - 10:15 Platform presentation of selected abstracts I (Congress Hall) Presence and severity of chronic cerebrospinal venous insufficiency is related to lower brain parenchyma venous vasculature visibility on susceptibility-weighted imaging in patients with multiple sclerosis 82

R. Zivadinov, G. Poloni, C. Schirda, C. Magnano, E. Carl, N. Bergsland, D. Hojnacki, C. Kennedy, F. Parker, M. Dwyer, B. Weinstock-Guttman (Buffalo, US)

Dr. Simka's research on endovascular treatment of CCSVI will be presented(波蘭醫師Simka的手術觀察研究)

15:30 - 17:00 Therapy disease-modifying - Others 2 Safety and complications related to endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients P 914

M. Simka, T. Ludyga, M. Kazibudzki, M. Hartel, M. Swierad, J. Piegza, P. Latacz, L. Sedlak, M. Tochowicz (Katowice, Zabrze, PL)

Dr. Zivadinov's research on utilizing MRV to visualize the jugular veins after angioplasty-

15:30 - 17:00 Imaging 2 Use of magnetic resonance venography for visualisation of the internal jugular veins in patients with multiple sclerosis diagnosed with chronic cerebrospinal venous insufficiency and treated with percutaneous angioplasty P 773

A. Lopez-Soriano, R. Zivadinov, R. Galeotti, D. Hojnacki, E. Menegatti, C. Schirda, A.M. Malagoni, K. Marr, C. Kennedy, I. Bartolomei, C. Magnano, F. Salvi, B. Weinstock-Guttman, P. Zamboni (Buffalo, US; Bologna, IT) 15:30 - 17:00 Clinical assessment tools 2

BNAC's correlation of CCSVI to MS(美國水牛城醫學中心的研究)

Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis P 653

B. Weinstock-Guttman, G. Cutter, K. Marr, D. Hojnacki, M. Ramanathan, R.H.B. Benedict, C. Morgan, E.A. Yeh, E. Carl, C. Kennedy, J. Reuther, C. Brooks, M. Elfadil, M. Andrews, R. Zivadinov (Buffalo, Birmingham, US)

Dr. Simka's correlation of severity of CCSVI with severity of MS(波蘭醫師Simka的手術觀察研究)

15:30 - 17:00 MS symptoms 2 Correlation of localisation and severity of extracranial venous lesions with clinical status of multiple sclerosis P 641

M. Simka, T. Ludyga, M. Kazibudzki, A. Adamczyk-Ludyga, J. Wrobel, P. Latacz, J. Piegza, M. Swierad (Katowice, PL)

A Beirut study that says CCSVI does not cause MS

15:30 - 17:00 Pathology 2 Chronic cerebrospinal venous insufficiency is an unlikely cause of multiple sclerosis P 663

B. Yamout, A. Herlopian, Z. Issa, R.H. Habib, A. Fawaz, J. Salameh, H. Wadih, H. Awdeh, N. Muallem, R. Raad, A. Al-Kutoubi (Beirut, LB)

Dr. Zivadinov's study showing increase of iron in gray matter of MS/CCSVI (鐵離子的堆積)

15:30 - 17:00 Imaging 2 Multiple sclerosis patients with chronic cerebrospinal venous insufficiency present with increased iron concentration on susceptibility-weighted imaging in deep-grey matter P 774

R. Zivadinov, M. Heininen-Brown, C. Schirda, C. Magnano, D. Hojnacki, C. Kennedy, E. Carl, N. Bergsland, S. Hussein, M. Cherneva, L. Willis, M. Dwyer, B. Weinstock-Guttman (Buffalo, US)

And finally, the German neurological doppler study where they claim they found no CCSVI, but Dr. Zamboni says their results actually PROVE CCSVI.(德國觀察的現象)

15:30 - 17:00 Diagnosis & differential diagnosis 2 No evidence for cerebro-cervical venous congestion in patients with multiple sclerosis P 579

F. Doepp, F. Paul, J.M. Valdueza, K. Schmierer, S.J. Schreiber (Berlin, Bad Segeberg, DE; London, UK)

And of course, the pharmaceutical companies will be there, presenting all their positive findings, sponsoring lectures and discussions and hosting dinners and events. What fun!

I actually wish I could go, but it's too far away, and too much going on at home. I hope we can get some reports from attendees, and I promise to link to those and any other news that comes out of the conference. I really wish we could all be flies on the wall as Dr. Omar Khan "questions" Dr. Zamboni.

我很希望我能夠去, 只可惜太遠了. 希望與會者能夠把一些內容post出來.
Share/Bookmark

1 則留言:

  1. 在歐洲多發性硬化症治療與研究委員會第26屆大會上,Biogen Idec公司呈報超過45項資料,展示其在多發性硬化症領域的全球領導地位

    (中央社訊息服務20101011 11:44:43)該公司強大的後期產品陣容可滿足多發性硬化症患者未獲滿足的需求、重新定義多發性硬化症的治療成功與否

    麻塞諸塞州WESTON -- (美國商業資訊) -- Biogen Idec公司 (NASDAQ: BIIB) 今天宣佈,2010年10月13-16日在瑞典Gothenburg召開的歐洲多發性硬化症治療與研究委員會 (ECTRIMS) 第26屆大會期間,將呈報超過45項公司及合作夥伴贊助的平台和壁報。ECTRIMS是世界上最大的專注於多發性硬化症 (MS) 研究及進展的醫學會議。呈報資料將包括Biogen Idec公司目前市售的產品TYSABRI (natalizumab) 和AVONEX (β-1a干擾素) 以及4個後期專案:fampridine持續性藥效錠、口服化合物BG-12 (富馬酸二甲酯,dimethyl fumarate)、β-1a聚乙二醇干擾素和daclizumab。

    Biogen Idec公司神經病學研發副總裁兼資深研究員John R. Richert醫學博士表示:「我們以領先的MS治療藥物AVONEX和TYSABRI全身心地承諾MS群體,這兩種藥物都在全球應用於各式各樣的患者。通過美國以外市場的法規流程,我們同樣在努力工作促進fampridine持續性藥效錠,它可望改善MS患者的行走能力。憑藉這3種進入後期臨床研究的化合物,Biogen Idec公司擁有了業界最深厚的後期產品線之一。我們不會滿足於現有的成績,將孜孜不倦地不斷工作直至找到這種疾病的根治方法。」

    來自業界最廣泛的MS產品線之一的資料
    fampridine持續性藥效錠
    將有6份壁報探討fampridine持續性藥效錠,該藥正在開發中,可望改善MS成人患者的行走功能。Biogen Idec公司從Acorda Therapeutics公司獲得在美國 (U.S.) 以外開發及商業化fampridine持續性藥效錠的授權。Acorda公司正在美國開發及商業化該化合物,該藥在美國核准應用的商品名是AMPYRA (dalfampridine) 10毫克持續性藥效錠。

    下列壁報的要點包括:
    •彙總分析顯示,多發性硬化症患者應用fampridine持續性藥效錠後行走速度加快 – 壁報P922
    •fampridine持續性藥效錠治療多發性硬化症開放延伸期研究分析 – 壁報P518
    BG-12 (富馬酸二甲酯)
    將有4份壁報和呈報探討BG-12。IIb期研究顯示,BG-12的安全性和有效性資料為陽性,支援該藥進入下一步研究。該研究結果同樣激勵了對BG-12 潛在神經保護作用的進一步評估。DEFINE和CONFIRM這2項III期臨床試驗已完成患者入組,預計在2011年可進行全套資料解讀。
    •多發性硬化症患者中磁化轉移影像可行性的跨中心試驗– 壁報 P764
    •BG-12在腦星狀細胞中顯示抗炎及促代謝效應 – 壁報 P879
    •BG-12口服與β-1a干擾素或glatiramer acetate聯合用藥的藥物動力學、安全性及耐受性 – 壁報 P478
    •氧化刺激後富馬酸二甲酯和單甲基富馬酸對人類脊索星狀細胞初級培養物的神經保護效應 – 壁報 P887
    β-1a聚乙二醇干擾素
    將有3份呈報探討β-1a聚乙二醇干擾素。β-1a聚乙二醇干擾素在患者體內的長效能力正在評估中,可望成為一種需要較少注射次數的MS治療藥物。ECTRIMS上呈報的資料支援在進行中的III期ADVANCE臨床研究中繼續評估該化合物,該研究目前正在入組患者。
    •ADVANCE β-1a聚乙二醇干擾素用於復發型多發性硬化症的3期研究:研究理由和設計 – 壁報 P904
    •開發一種高通量全血表達譜方法來鑑定健康對照受試者中β-1a干擾素或β-1a聚乙二醇干擾素誘導的基因 – 壁報 P971
    •健康志願者中β-1a干擾素和β-1a聚乙二醇干擾素誘導的Th17 調控網路相關的藥理學變化 – 壁報 P968

    關於fampridine持續性藥效錠
    fampridine 持續性藥效錠用於改善MS成人患者的行走功能。研究顯示,fampridine持續性藥效錠能加快受損神經的傳導速度,從而提升神經功能。Acorda Therapeutics公司正在美國開發及商業化這一持續性藥效錠。該藥在美國核准應用的商品名是AMPYRA (dalfampridine) 10毫克持續性藥效錠。按照與Acorda公司簽署的一項授權協議,Biogen Idec公司正計畫在美國以外商業化該產品。

    關於BG-12
    BG-12 (BG00012, 富馬酸二甲酯) 是一種研究中的口服藥物,正在進行治療復發-緩解型MS的III期臨床開發,該型是MS最常見的類型;同時正在進行治療類風濕性關節炎的II期試驗。 BG-12治療MS的申請已獲得美國食品藥品管理局 (FDA) 的快速審核(Fast Track)資格,這將加快其在美國的法規審核。Biogen Idec公司擁有BG-12全球商業化的所有權益。

    關於β-1a聚乙二醇干擾素
    β- 1a聚乙二醇干擾素治療復發型MS的研究正在進行中,目前一項III期臨床試驗正在入組受試者。β-1a聚乙二醇干擾素經皮下注射給藥,其在患者體內的長效能力正在評估中,可望成為一種需要較少注射次數的MS治療藥物。有興趣瞭解有關ADVANCE 試驗更多情況的患者可接洽他們的醫師或傳送電子郵件至 ADVANCEstudy@biogenidec.com。

    關於daclizumab
    daclizumab是一種人類化單株抗體(humanized monoclonal antibody),與高度親和力IL-2受體的CD25 α亞單位結合。在靜息T細胞 (免疫細胞) 上,CD25的表達處於低水準,而在應答諸如MS等自身免疫疾病時能夠啟動的T細胞上,其表達處於高水準。一般相信,daclizumab的作用機理是與已啟動的T細胞上的這種受體選擇性結合,並抑制該受體,但不會引起T細胞損耗。亞培公司正與Biogen Idec 公司合作進行daclizumab作為研究新藥治療MS的臨床開發。daclizumab治療MS的2項註冊臨床試驗正在進行中。有興趣瞭解有關 DECIDE試驗更多情況的患者可接洽他們的醫師或傳送電子郵件至DECIDEstudy@biogenidec.com。

    回覆刪除

留言